Halozyme Therapeutics, Inc. - Common Stock (HALO)
Healthcare › Biological Products, (No Diagnostic Substances)
Price History
Feb 9, 2026 — Aug 24, 2026Investment Snapshot
- Trading 705% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 5/9 — moderate financial health
- Strong ROE of 501.8% with 46.8% net margin
- Revenue growing at 38% annually
Halozyme Therapeutics, Inc. - Common Stock (HALO) is a Healthcare company operating in Biological Products, (No Diagnostic Substances), listed on the NASDAQ , with a market capitalisation of $12.3 billion . Key value metrics: P/E ratio 17.0, P/B ratio 85.53, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Halozyme Therapeutics, Inc. - Common Stock — Fundamental Analysis Summary
Halozyme Therapeutics, Inc. - Common Stock (HALO) is currently trading 705% above its Graham Number of $13.44, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries a reasonable trailing P/E ratio of 17.0x.
On financial health, HALO shows a moderate Piotroski F-Score of 5/9, and strong return on equity of 501.8% (sector average: -20.1%), and high leverage with a debt-to-equity ratio of 13.50.
StockPik's composite Value Score for HALO is 59/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
HALO reports a high gross margin of 83.1% (sector average: 37.4%) and a strong operating margin of 58.0%.
HALO shows revenue growing at 38% year-over-year, with earnings declining at 29%.